Health In Tech Announces Closing of Initial Public Offering
Lula Grants Legal Protection to More Indigenous Lands in BrazilSophie Hediger, a member of Switzerland's snowboard cross team at the 2022 Beijing Winter Olympics, has died following an avalanche at a mountain resort, the country's skiing federation said on Tuesday. The incident occurred on Monday at the Arosa resort in Switzerland. Hediger, 26, competed at the Beijing Games in the women’s snowboard cross and the mixed team version of the same event. Hediger achieved her first two World Cup podium finishes in the 2023-24 season. Her best result was a second place in St. Moritz in January. “We are shocked and our thoughts are with Sophie’s family, to whom we offer our deepest condolences,” said Swiss-Ski CEO Walter Reusser in a statement. “(She lost her life) tragically, brutally and far too soon.” AP sports: https://apnews.com/sportsNone
NEW YORK--(BUSINESS WIRE)--Dec 10, 2024-- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to the Company’s initial public offering conducted on February 7, 2024 (the “IPO”). Kyverna is a “clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.” For more information, submit a form , email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Kyverna Therapeutics, Inc. (NASDAQ: KYTX) Misled Investors Regarding its Business Operations. According to the lawsuit, the registration statement and prospectus used to effectuate Kyverna’s IPO misstated and/or omitted facts concerning the results of Kyverna’s ongoing evaluation of KYV-101, Kyverna’s lead product candidate, in clinical trials. Specifically, Kyverna touted patient “improvement” in certain indicators while failing to disclose adverse data regarding one of Kyverna’s trials, which adverse data was known to Kyverna at the time of the IPO. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Kyverna Therapeutics, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by February 7, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. View source version on businesswire.com : https://www.businesswire.com/news/home/20241210356721/en/ CONTACT: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com KEYWORD: NEW YORK UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: The Rosen Law Firm, P.A. Copyright Business Wire 2024. PUB: 12/10/2024 04:19 PM/DISC: 12/10/2024 04:20 PM http://www.businesswire.com/news/home/20241210356721/enEnergia All-Ireland League Men’s Divisions: Round 9 Results Round-Up
Teel tallies 20, Harding posts double-double as Sycamores defeat Chicago State 97-61
NoneMarvell Technology Introduces 1.6 Tbps LPO Chipset to Enable Optical Short-reach, Scale-up Compute Fabric Interconnects
A provincial mining industry leader says B.C. could end up profiting from trade tensions between China and the United States over critical minerals. Michael Goehring, president and chief executive officer of the Mining Association of British Columbia, said Wednesday, (Dec. 4), that China's decision to ban exports of certain critical minerals and rare earths to the United States demonstrates why it is "vital" for Canada and the U.S. to reduce their dependence on authoritarian regimes for critical mineral supplies and mineral processing. "British Columbians can play a key role in providing the critical minerals the U.S. and our other allies need in the years to come," Goehring said. "B.C. has, or produces, 16 of the 50 minerals the United States has identified as being critical to the nation’s economic and national security. In fact, seven per cent of B.C.’s exports to the US in 2022 were critical minerals and metals, including aluminum, germanium, gallium, indium, lead and zinc." China announced Tuesday, (Dec. 3), that it would immediately ban sales of gallium and germanium among other minerals to the United States following the U.S.'s decision to limit Chinese access to American-made digital technology. China is world's leading supplier of many minerals used in technologies deemed critical in fields like transportation, communication and alternative energy, all of which have a military and security dimension. Chinese efforts to use its dominance in these materials as leverage have not gone unnoticed, as several western jurisdictions have sought out alternative suppliers, including Canada. "In fact, Canada and the U.S. initiated the Joint Action Plan on Critical Minerals Collaboration in 2020 under President Trump to reduce our vulnerability," Goehring said." China’s export ban highlights the need to accelerate our efforts through the Joint Action Plan to grow a resilient North American critical mineral supply chain and advance our mutual economic, defense and security objectives." Whether Goehring's appeal will resonate among decision-makers on either side of the U.S-Canada border is a different question given the prospect of trade tensions with Trump returning to the White House next month. With 17 new critical mineral projects under development, Britisch Columbia can make what Goehring called "a meaningful contribution to North America’s future" while creating jobs for workers, stability for resource communities and shared prosperity throughout B.C. "But these benefits can only be realized if we modernize and expedite the mine permitting and approval process," he said. "(We) are in a race and we need to act quickly. Ongoing permitting delays and uncertainty needlessly drive away investment and lead to deferred or unrealized economic benefits. We need mine permitting to be a competitive advantage for our province."“Has Burner Accounts!”: Skip Bayless Points Out Irony in LeBron James Sharing Kevin Durant’s Agent’s Post About Toxicity
ISRO's Orbital Tapestry: Weaving together docking, research, debris mitigation with SpaDEXGift Guide 2024: A gift for the person who has everything
AP Sports SummaryBrief at 5:52 p.m. ESTVadnais Heights-based H.B. Fuller on Monday announced two small acquisitions and a divestiture as it reshapes its portfolio of adhesive technologies towards higher-growth, higher-margin solutions. Fuller announced deals for GEM S.r.l. and Medifill Ltd., small medical adhesive companies based in Europe that will join its Health, Hygiene and Consumables segment. The deals are expected to close in February for a combined purchase price of about $189 million. Medifill is based in Dublin, Ireland, and produces medical-grade adhesives used in wound closures. GEM is an Italian company that makes medical adhesives and application devices used in dozens of surgical indications. Adhesives can be used in place of sutures, staples and other agents that stop blood loss and can produce better results while reducing operating times. “With the purchase of GEM, Medifill, and our previous acquisitions in this space, H.B. Fuller has now built a Medical Adhesive Technologies (MAT) business founded on our expertise in cyanoacrylate chemistry, and we have extended our penetration into a global footprint,” Celeste Mastin, president and chief executive of H.B. Fuller, said in a news release. Medifill and GEM will add to Fuller’s other MAT businesses acquired recently, including Cyberbond, Tissue Seal, and Adhezion Biomedical. GEM will serve as a European headquarters for H.B. Fuller’s MAT business. H.B. Fuller also announced Monday that it sold a flooring adhesives business as part of a broader move to reshape some existing business in a new global business unit named Building Adhesives Solutions (BAS). The BAS business will consist of some solutions in its Construction Adhesives and Engineering Adhesives segments. Financial reporting of the new business will be effective at the start of H.B. Fuller’s fiscal 2025, which started Dec. 1. “This move is consistent with our strategy to drive our portfolio and capital allocation to the highest-margin, fastest-growing segments of the $80 billion global adhesives industry,” Mastin said in a release announcing the sale of the flooring business. A Los Angeles-based private equity firm, Pacific Avenue Capital Partners, acquired the flooring business for $80 million. The business had annual revenue of approximately $160 million and earnings of $15 million. Mastin joined H.B. Fuller early in 2022 and was named CEO that December. A longtime executive in the adhesives and petrochemicals industry, she was most recently CEO at PetroChoice Lubrication Solutions. Mastin has overseen eight acquisitions since being named CEO of H.B. Fuller. Shares of H.B. Fuller closed at $76.96 a share on Monday, up less than 1%. Over the last 52 weeks shares have traded between $72.60 and $87.67.